Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Grille

Interventional Pain Medicine Hartford, CT Medical Doctor

NPI 1659630960 CMS profile 2781859

31 Seymour St Ste 201, Hartford, CT 06106

Open in the dashboard

General payments

$10,102

234 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Grille of Hartford, CT is reported in the CMS Open Payments database as having received $10,102 across 234 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,016 27
2024 General $1,129 24
2023 General $1,455 25
2022 General $1,805 15
2021 General $1,108 28
2020 General $1,007 30
2019 General $2,580 85

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Grille
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Michael Grille were reported at $1,016. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Michael Grille Interventional Pain Medicine median Middle half National median
2019 $2,580 $684 $216–$2,079 $163
2020 $1,007 $382 $122–$1,109 $114
2021 $1,108 $552 $167–$1,554 $132
2022 $1,805 $605 $187–$1,924 $149
2023 $1,455 $671 $195–$1,915 $160
2024 $1,129 $684 $206–$1,837 $164
2025 $1,016 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $3,365 45 payments
  2. Abbott Laboratories $1,581 15 payments
  3. SPR Therapeutics, Inc $494 12 payments
  4. Scilex Pharmaceuticals Inc. $406 18 payments
  5. Vertos Medical, Inc. $327 4 payments
  6. Medtronic, Inc. $324 8 payments
  7. Curonix LLC $241 3 payments
  8. Allergan Inc. $224 11 payments
  9. Bioventus LLC $197 5 payments
  10. Pacira Pharmaceuticals Incorporated $189 3 payments
  11. Other $2,755 110 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,736 228 payments
  2. Travel and Lodging $921 5 payments
  3. Education $444 1 payment
Products named General payments · program years 2019–2025
  1. WaveWriter Alpha Prime 16 $956 3 payments
  2. GENERAL PAIN MANAGEMENT $669 17 payments
  3. General - Pain Management General - Pain Management_NMD $540 4 payments
  4. GENERAL - PAIN MANAGEMENT Pain Management $540 13 payments
  5. SPRINT PNS System $494 12 payments
  6. Axium INS DRG IPG $444 1 payment
  7. mild Device Kit $327 4 payments
  8. Proclaim IPG $325 4 payments
  9. ZTLido $292 13 payments
  10. INTELLIS ADAPTIVESTIM $282 6 payments
  11. Other $4,903 168 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

942

Median for Interventional Pain Management: 1,220

Drug cost

$83,477

Median for Interventional Pain Management: $39,344

Branded share of claims

15.6%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 53 $30,486
Ztlido Lidocaine Brand 26 $17,870
Nucynta Tapentadol Hcl Brand 17 $12,421
Lidocaine Generic 46 $5,367
Morphine Sulfate Er Morphine Sulfate Brand 12 $3,169
Pregabalin Generic 158 $3,100
Buprenorphine Generic 15 $2,795
Gabapentin Generic 178 $2,601
Oxycodone Hcl Generic 43 $1,043
Diclofenac Sodium Generic 29 $739

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$74,332

Of which drugs: $14,159

Medicare patients

142

Average age 72

Services billed

3,547

96 women, 46 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 69%
Depression 48%
Diabetes 32%
Ischemic heart disease 27%
Chronic kidney disease 25%
Osteoporosis 24%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 15 104 $82

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZTLido
  • Scilex Pharmaceuticals Inc. $104
$104 26 —
Prialt
  • TerSera Therapeutics LLC $54
$54 — —
BOTOX
  • AbbVie, Inc. $31
$31 — —
UBRELVY
  • AbbVie, Inc. $11
$11 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

234 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record